May 2004
Volume 45, Issue 13
ARVO Annual Meeting Abstract  |   May 2004
Conjunctival Hyperemia Related to Bimatoprost Treatment is Not Associated with Signs of Inflammation
Author Affiliations & Notes
  • J. Chen
    Biological Science,
    Allergan Inc, Irvine, CA
  • R. Susanna, Jr.
    Ophthamology, University de Sao Paulo, Sao Paulo, Brazil
  • R. David
    Ophthalmology Clinical Research,
    Allergan Inc, Irvine, CA
  • D.F. Woodward
    Biological Science,
    Allergan Inc, Irvine, CA
  • J.M. Holland
    Safety Evaluation,
    Allergan Inc, Irvine, CA
  • L.A. Wheeler
    Biological Science,
    Allergan Inc, Irvine, CA
  • Footnotes
    Commercial Relationships  J. Chen, Allergan Inc E; R. Susanna, Jr., Allergan Inc F; R. David, Allergan Inc E; D.F. Woodward, Allergan Inc E; J.M. Holland, Allergan Inc E; L.A. Wheeler, Allergan Inc E.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 2609. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. Chen, R. Susanna, Jr., R. David, D.F. Woodward, J.M. Holland, L.A. Wheeler; Conjunctival Hyperemia Related to Bimatoprost Treatment is Not Associated with Signs of Inflammation . Invest. Ophthalmol. Vis. Sci. 2004;45(13):2609.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: To investigate the possible involvement of ocular inflammation and the mechanism of conjunctival hyperemia associated with bimatoprost treatment in patients and laboratory animals. Methods: Ocular inflammation was evaluated in bimatoprost–treated glaucoma and OHT patients using laser–flare photometry, biomicroscopy, and histopathologic evaluation of bulbar conjunctival specimens. In–life observations and histopathological assessment of ocular tissues were conducted for multiple–dose chronic safety studies (one–month to 52–weeks) in rabbits, dogs, and monkeys. Vascular effects of bimatoprost were evaluated using the rabbit endothelium–intact and endothelium–denuded precontracted isolated jugular vein preparation. Ocular surface hyperemia grading was performed in dogs dosed topically with bimatoprost in the presence and absence of a nitric oxide synthase inhibitor L–NAME. Results: The conjunctiva and anterior chamber of patients exhibited no signs of ocular inflammation associated with bimatoprost treatment. Similarly, preclinical safety studies showed no evidence of treatment–related inflammation in ocular tissues of rabbits, dogs, and monkeys. Bimatoprost produced weak vasorelaxant responses in the endothelium–intact rabbit jugular vein preparations, but was inactive in preparations where the vascular endothelium had been removed. Conjunctival hyperemia in dogs treated with bimatoprost was significantly inhibited by L–NAME. Conclusions: Conjunctival hyperemia related to bimatoprost treatment is not associated with inflammation, neither intraocular nor at the ocular surface, in patients and laboratory animals. The mechanism of conjunctival hyperemia appears to occur by vasodilatation and involves endothelium–derived nitric oxide. These studies indicate that conjunctival hyperemia is a non–inflammatory, pharmacologically–based vasodilatation, side effect of bimatoprost treatment.

Keywords: conjunctiva • eicosanoids • nitric oxide 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.